Ryan Maynard Biography and Net Worth

Director of Iovance Biotherapeutics

Mr. Maynard currently serves as Chief Financial Officer of Cara Therapeutics, Inc., a publicly-traded commercial-stage biopharmaceutical company. He previously served as the Chief Financial Officer of Paulus Holdings Ltd. d/b/a LetsGetChecked. Prior to LetsGetChecked, he was the Chief Financial Officer of Blade Therapeutics, Inc., a privately held biotechnology company. Mr. Maynard has served in various executive roles at Rigel Pharmaceuticals, Inc., a public commercial-stage drug development company, including 10 years as Chief Financial Officer. He also served as Corporate Controller and Director of Finance and Accounting for Personify, Inc., an e-commerce software company, and Controller of General Magic, Inc. Mr. Maynard has held various positions at Siliconix, Inc., including Senior Finance Manager. He previously worked at Ernst and Young LLP. He holds a B.S. in Commerce–Accounting from Santa Clara University.

What is Ryan D. Maynard's net worth?: The estimated net worth of Ryan D. Maynard is at least $16.50 thousand as of November 12th, 2024. Mr. Maynard owns 7,500 shares of Iovance Biotherapeutics stock worth more than $16,500 as of December 4th. This net worth approximation does not reflect any other investments that Mr. Maynard may own. Learn More about Ryan D. Maynard's net worth.
How do I contact Ryan D. Maynard?: The corporate mailing address for Mr. Maynard and other Iovance Biotherapeutics executives is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. Iovance Biotherapeutics can also be reached via phone at (650) 260-7120 and via email at [email protected]. Learn More on Ryan D. Maynard's contact information.
Has Ryan D. Maynard been buying or selling shares of Iovance Biotherapeutics?: Ryan D. Maynard has not been actively trading shares of Iovance Biotherapeutics in the last ninety days. Most recently, Ryan D. Maynard sold 50,000 shares of the business's stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $10.06, for a transaction totalling $503,000.00. Following the completion of the sale, the director now directly owns 7,500 shares of the company's stock, valued at $75,450. Learn More on Ryan D. Maynard's trading history.
Who are Iovance Biotherapeutics' active insiders?: Iovance Biotherapeutics' insider roster includes Iain Dukes (Director), Ryan Maynard (Director), Raj Puri (Chief Regulatory Officer), Wayne Rothbaum (Director), and Frederick Vogt (CEO). Learn More on Iovance Biotherapeutics' active insiders.
Are insiders buying or selling shares of Iovance Biotherapeutics?: In the last twelve months, Iovance Biotherapeutics insiders bought shares 1 times. They purchased a total of 5,600 shares worth more than $9,744.00. The most recent insider tranaction occured on May, 23rd when insider Raj K Puri bought 5,600 shares worth more than $9,744.00. Insiders at Iovance Biotherapeutics own 10.3% of the company. Learn More about insider trades at Iovance Biotherapeutics.
Information on this page was last updated on 5/23/2025.

Ryan D. Maynard Insider Trading History at Iovance Biotherapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/12/2024	Sell	50,000	$10.06	$503,000.00	7,500

Ryan D. Maynard Buying and Selling Activity at Iovance Biotherapeutics

Iovance Biotherapeutics Company Overview

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Today's Range

Now: $2.20

$2.16

$2.24

50 Day Range

MA: $2.24

$1.81

$2.65

2 Week Range

Now: $2.20

$1.64

$9.30

Volume

8,728,222 shs

Average Volume

16,249,413 shs

Market Capitalization

$873.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83